布拉氏酵母菌益生菌相关真菌血症及其他真菌感染
该研究评估了芬兰5所大学医院2009–2018年所有酵母菌属检出患者,发现46例酵母菌血症中至少20例(43%)使用布拉氏酵母菌益生菌,使用该益生菌的比值比为14(95%CI 4–44)。在1153例非血液培养检出中抽查125例,至少24例(19%)使用该益生菌(比值比10,95%CI 3–32)。提示胃肠道完整性可能受损者应慎用此类益生菌。
要点
- 酵母菌血症患者中使用布拉氏酵母菌益生菌的比例为43%,比值比14。
- 非血液酵母菌培养检出者中19%使用该益生菌,比值比10。
- 胃肠道完整性可能受损的患者应慎重考虑使用布拉氏酵母菌益生菌。
核心结论
- 布拉氏酵母菌益生菌使用与酵母菌血症及其他临床酵母菌培养检出相关。
研究设计与样本
- 回顾性研究,评估芬兰5所大学医院2009–2018年所有酵母菌属检出患者的医疗记录。
主要发现
- 46例酵母菌血症患者中至少20例(43%)使用布拉氏酵母菌益生菌,对照组为菌血症或念珠菌血症患者,使用该益生菌的比值比为14(95%CI 4–44)。
- 1153例非血液培养检出中抽查125例,至少24例(19%)使用该益生菌,比值比为10(95%CI 3–32)。
临床怎么用
- 对胃肠道完整性可能受损的患者,应慎重考虑使用布拉氏酵母菌益生菌补充剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Because of widespread use of probiotics, their safety must be guaranteed. We assessed use of Saccharomyces boulardii probiotic yeast from medical records for patients who had Saccharomyces fungemia or other clinical Saccharomyces culture findings. We evaluated all Saccharomyces sp. findings at 5 university hospitals in Finland during 2009–2018. We found 46 patients who had Saccharomyces fungemia; at least 20 (43%) were using S. boulardii probiotic. Compared with a control group that had bacteremia or candidemia, the odds ratio for use of an S. boulardii probiotic was 14 (95% CI 4–44). Of 1,153 nonblood culture findings, the history for 125 patients was checked; at least 24 (19%) were using the probiotic (odds ratio 10, 95% CI 3–32). This study adds to published fungemia cases linked to use of S. boulardii probiotic and sheds light on the scale of nonblood Saccharomyces culture findings that are also linked to use of this probiotic. Use of these supplements should be considered carefully for patients whose gastrointestinal tract integrity might be compromised.
引用
- Rannikko J, Holmberg V, Karppelin M, et al. Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements. Emerg Infect Dis. 2021. PMID: 34287140. doi:10.3201/eid2708.210018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。